CPL500036 - low dose + CPL500036 - high dose + Placebo

Phase 2Completed

1 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Parkinson Disease

Conditions

Parkinson Disease, Dyskinesia, Medication-Induced

Trial Timeline

Nov 2, 2021 → Jan 27, 2025

NCT ID

NCT05297201

About CPL500036 - low dose + CPL500036 - high dose + Placebo

CPL500036 - low dose + CPL500036 - high dose + Placebo is a phase 2 stage product being developed by Celon Pharma for Parkinson Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT05297201. Target conditions include Parkinson Disease, Dyskinesia, Medication-Induced.

What happened to similar drugs?

20 of 20 similar drugs in Parkinson Disease were approved

Approved (20) Terminated (3) Active (0)

✅Mirabegron + PlaceboAstellas PharmaApproved

✅Lemborexant + placeboEisaiApproved

✅Safinamide MesilateEisaiApproved

✅Istradefylline PillKyowa KirinApproved

✅Levodopa-carbidopa intestinal gel (LCIG)AbbVieApproved

✅Carbidopa/levodopa/entacaponeNovartisApproved

✅Carbidopa/levodopa/entacapone + Immediate release carbidopa/levodopaNovartisApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05297201	Phase 2	Completed	Nov 2, 2021	Jan 27, 2025	Parkinson Disease
NCT05278156	Phase 2	Completed	May 19, 2021	Jun 19, 2024	Schizophrenia

Competing Products

20 competing products in Parkinson Disease

See all competitors

Product	Company	Stage	Hype Score
exidavnemab + Placebo Comparator	BioArctic AB	Phase 2	36
UB-312 + Placebo	Vaxxinity	Phase 1	19
NAV5001 + DaTscan	Navidea Biopharmaceuticals	Phase 3	22
LY4006896 + Placebo	Eli Lilly	Phase 1	36
ATH-1017 + Placebo	LeonaBio	Phase 2	17
piclozotan + 0.9% sodium chloride (normal saline)	Daiichi Sankyo	Phase 2	35
Mirabegron + Placebo	Astellas Pharma	Approved	43
E2007	Eisai	Phase 3	32
ARICEPT	Eisai	Phase 3	40
Perampanel	Eisai	Phase 3	32
GPI 1485	Eisai	Phase 2	35
E2007	Eisai	Phase 3	40
Prior Donepezil 5mg + Prior Donzepezil 10mg + Prior Placebo	Eisai	Phase 3	40
Equfina 50 mg	Eisai	Pre-clinical	26
Equfina	Eisai	Pre-clinical	26
perampanel + placebo	Eisai	Phase 2	27
Lemborexant + placebo	Eisai	Approved	50
Placebo + E2007 + E2007	Eisai	Phase 3	32
Safinamide Mesilate	Eisai	Approved	43
E2007 + E2007 + E2007	Eisai	Phase 2	35